Market Access News | pharmaphorum

News

UK orders 60m 'booster' doses of Pfizer/BioNTech COVID vacci...

The UK has ordered an extra 60 million doses of the Pfizer/BioNTech COVID-19 vaccine, which could be used as a potential booster campaign in the autumn.

News

Ardelyx’s-ambition-to-revolutionise-kidney-treatment

FDA sets September review date for Calliditas' rare kidney d...

Calliditas Therapeutics could have its first product on the market in the US this autumn, as the FDA has now started a priority review of Nefecon for rare disease primary IgA nephropathy (I

News

Talking vaccines: Industry’s role in protecting the Gavi generation

European Commission legal battle with AZ over COVD vaccines ...

The European Commission has officially begun legal proceedings against AstraZeneca over supplies of COVID vaccines.

News

US to share 60m AZ coronavirus vaccines with rest of world

The US has said it will share up to 60 million doses of its AstraZeneca vaccine with other countries as they become available, after criticism it was hoarding the shots while other countrie

News

CHMP backs Roche's Enspryng for rare nerve disease NMOSD

Roche's Enspryng has been recommended for approval in the EU for treating neuromyelitis optica spectrum disorder (NMOSD), extending the treatment options for people with the life-threatenin

News

Calliditas eyes 2022 approval in EU for rare kidney disease ...

Calliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN), in the first half of 2022 after getting the green light for an acc

UK orders 60m 'booster' doses of Pfizer/BioNTech COVID vacci...

FDA sets September review date for Calliditas' rare kidney d...

European Commission legal battle with AZ over COVD vaccines ...

US to share 60m AZ coronavirus vaccines with rest of world

CHMP backs Roche's Enspryng for rare nerve disease NMOSD

Calliditas eyes 2022 approval in EU for rare kidney disease ...

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks